Anti-diabetic drugs and weight loss in patients with type 2 diabetes

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830

10-year follow-up of intensive glucose control in type 2 diabetes

Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382

Global and societal implications of the diabetes epidemic

Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559

Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications

Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358

Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus

Bláhová, J., Martiniaková, M., Babikova, M., Kováčová, V., Mondočková, V., & Omelka, R. (2021) · Pharmaceuticals · doi:10.3390/ph14080806 · Cited by 333

The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation

Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142

GLP-1 receptor agonist as a modulator of innate immunity

Chen, J., Mei, A., Wei, Y., Li, C., Qian, H., Min, X., Yang, H., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997578 · Cited by 120

Tirzepatide: A Systematic Update

Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S. S., Mone, P., & Santulli, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314631 · Cited by 118

Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age

Lisco, G., Disoteo, O., Tullio, A. D., Geronimo, V. D., Giagulli, V. A., Monzani, F., Jirillo, E., Cozzi, R. C., Guastamacchia, E., Pergola, G. D., et al. (2023) · Nutrients · doi:10.3390/nu16010063 · Cited by 111

Management of diabesity: Current concepts

Michaelidou, M., Pappachan, J. M., & Jeeyavudeen, M. S. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i4.396 · Cited by 97

SGLT2-inhibitors are effective and safe in the elderly: the SOLD study

Lunati, M. E., Cimino, V., Gandolfi, A., Trevisan, M., Montefusco, L., Pastore, I., Pace, C., Betella, N., Favacchio, G., Bulgheroni, M., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106396 · Cited by 77

Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study

Volpe, S., Lisco, G., Racaniello, D., Fanelli, M., Colaianni, V., Vozza, A., Triggiani, V., Sabbà, C., Tortorella, C., De Pergola, G., et al. (2022) · Nutrients · doi:10.3390/nu14122414 · Cited by 67

A polysaccharide from Inonotus obliquus ameliorates intestinal barrier dysfunction in mice with type 2 diabetes mellitus

Su, L., Xin, C., Yang, J., Dong, L., Mei, H., Dai, X., & Wang, Q. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.06.071 · Cited by 67

A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications

Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 71

A green QuEChERS syringe filter based micro-solid phase extraction using hydrophobic natural deep eutectic solvent as immobilized sorbent for simultaneous analysis of five anti-diabetic drugs by HPLC-UV

Khodayari, P., & Ebrahimzadeh, H. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.341765 · Cited by 59

Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?

Domingo, E., Marqués, P., Francisco, V., Piqueras, L., & Sanz, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107058 · Cited by 63

The impact of dietary fructose on gut permeability, microbiota, abdominal adiposity, insulin signaling and reproductive function

Güney, C., Bal, N. B., & Akar, F. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18896 · Cited by 53

Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials

Cai, W., Zhang, R., Yao, Y., Wu, Q., & Zhang, J. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1277113 · Cited by 54

Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting

Hu, Y., Zheng, S.-L., Ye, X.-L., Shi, J.-N., Zheng, X.-W., Pan, H.-S., Zhang, Y.-W., Yang, X.-L., & Huang, P. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-200 · Cited by 45

Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT ‐1 trial

Hankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Stefanski, A., & Garvey, W. T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15269 · Cited by 44

Sulforaphane: A nutraceutical against diabetes-related complications

Mthembu, S. X. H., Mazibuko-Mbeje, S. E., Moetlediwa, M. T., Muvhulawa, N., Silvestri, S., Orlando, P., Nkambule, B. B., Muller, C. J. F., Ndwandwe, D. E., Basson, A. K., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106918 · Cited by 37

Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network

Nassar, M., Nassar, O., Abosheaishaa, H. M., & Misra, A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02466-4 · Cited by 34

Optimizing metformin therapy in practice: Tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes

Silverii, G. A. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15749 · Cited by 33

Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets

Folli, F. B., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., Berra, C., Fiorina, P., Davalli, A. M., Rosa, S. L., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2023 · Cited by 32

Muscle loss and GLP-1R agonists use

Rossi, G., Bucciarelli, L., Mananguite, C.-L., Giovarelli, M., & Fiorina, P. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02611-2 · Cited by 31

Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide

Lunati, M. E., Cimino, V., Bernasconi, D. P., Gandolfi, A., Morpurgo, P. S., Tinari, C., Lazzaroni, E., Baruffaldi, L., Muratori, M., Montefusco, L. B., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107040 · Cited by 31

Metformin: From diabetes to cancer to prolongation of life

Sirtori, C. R., Castiglione, S., & Pavanello, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107367 · Cited by 38

Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential

AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30

Diabetes increases mortality in patients with pancreatic and colorectal cancer by promoting cachexia and its associated inflammatory status

Chovsepian, A., Prokopchuk, O., Petrova, G., Gjini, T., Kuzi, H., Heisz, S., Janssen, K., Martignoni, M. E., Friess, H., Hauner, H., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101729 · Cited by 30

Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases

Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)

Berra, C. C., Rossi, M. C., Mirani, M., Ceccarelli Ceccarelli, D., Romano, C., Sassi, L., Peretti, E., Favacchio, G., Pastore, I., Folini, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1099451 · Cited by 28

Tirzepatida: Un Avance Revolucionario en el Tratamiento de la Diabetes Mellitus Tipo 2 y la Obesidad

Chávez, M. (2023) · Revista Veritas de Difusão Cientifica. · doi:10.61616/rvdc.v4i1.39 · Cited by 28

The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration

Cencioni, C., Malatesta, S., Benedetti, V. V., Licursi, V., Perfetto, L., Conte, F., Ranieri, D., Bartolazzi, A., Kunkl, M., Tuosto, L., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03263-w · Cited by 31

Dulaglutide provides protection against sepsis-induced lung injury in mice by inhibiting inflammation and apoptosis

Wang, Y., Deng, F., Zhong, X., Du, Y., Fan, X., Su, H., & Pan, T. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175730 · Cited by 30

Sex differences in the weight response to GLP-1RA in people with type 2 diabetes. A long-term longitudinal real-world study

Marassi, M., Cignarella, A., Russo, G. T., Nollino, L., Strazzabosco, M., Marzullo, P., Leonetti, F., Avogaro, A., Consoli, A., & Fadini, G. P. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107866 · Cited by 33

Impact of high-intensity interval training on cardiometabolic health in patients with diabesity: a systematic review and meta-analysis of randomized controlled trials

Al-Mhanna, S. B., Franklin, B. A., Tarnopolsky, M. A., Hawley, J. A., Jakicic, J. M., Stamatakis, E., Little, J. P., Pescatello, L. S., Riebe, D. A., Thompson, W. R., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01974-4 · Cited by 29

Medical treatment of weight loss in children and adolescents with obesity

Calcaterra, V., Rossi, V., Mari, A., Casini, F., Bergamaschi, F., Zuccotti, G., & Fabiano, V. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106471 · Cited by 25

Efficacy of artemisinin and its derivatives in animal models of type 2 diabetes mellitus: A systematic review and meta-analysis

Wu, T., Feng, H., He, M., Yue, R., & Wu, S. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105994 · Cited by 22

Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: A double‑blind, randomized controlled clinical trial

Sun, L., Yuan, Y., Li, Y., & Rao, X. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11948 · Cited by 20

Comparative effects of nutraceuticals on body weight in adults with overweight or obesity: A systematic review and network meta-analysis of 111 randomized clinical trials

Shahinfar, H., Jayedi, A., Torabynasab, K., Payandeh, N., Martami, F., Moosavi, H., Bazshahi, E., & Shab‐Bidar, S. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106944 · Cited by 22

Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity

Ramms, B., Pollow, D. P., Zhu, H., Nora, C., Harrington, A. R., Omar, I., Gordts, P. L. S. M., Wortham, M., & Sander, M. (2022) · Diabetes · doi:10.2337/db21-1131 · Cited by 21

New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk

Branković, M., Dukić, M., Gmizić, T., Popadić, V., Nikolić, N., Sekulic, A. D., Brajković, M., Đokić, J., Mahmutović, E., Lasica, R., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14020229 · Cited by 21

Therapeutic strategies targeting mechanisms of macrophages in diabetic heart disease

Zhang, C., Shi, Y., Liu, C., Sudesh, S. M., Zhao, H., Li, P., Liu, Q., Ma, Y., Shi, A., & Cai, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02273-4 · Cited by 24

GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes

Gitto, M., Catapano, F., Francone, M., Mincione, G., Scialò, V., Pivato, C. A., Lisi, C., Regazzoli, D., Cao, D., Fiorina, R. M., et al. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02606-z · Cited by 21

Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment

Lok, K.-H., Wareham, N. J., Nair, R. S., How, C. W., & Chuah, L. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106237 · Cited by 19

An updated patent review of GLP-1 receptor agonists (2020-present)

Lu, W., Zhou, Z., Jiang, N., & Han, J. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2274905 · Cited by 17

The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Mahar, M. U., Mahmud, O., Ahmed, S., Qureshi, S. A., Kakar, W. G., & Fatima, S. S. (2024) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes24008 · Cited by 24

Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study

Lazzaroni, E., Lunati, M. E., Montefusco, L. B., Pastore, I., Chebat, E., Cimino, V., Morpurgo, P. S., Muratori, M., Plebani, L., Bolla, A. M., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106374 · Cited by 17

Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis

Yu, Y., Hu, G., Yin, S., Yang, X., Zhou, M., & Jian, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.990182 · Cited by 18

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study

Berra, C., Manfrini, R., Bifari, F., Cipponeri, E., Ghelardi, R., Centofanti, L., Mortola, U., Lunati, E., Bucciarelli, L. G., Cimino, V., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107517 · Cited by 19

Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care

Cherney, D. Z. I., Bell, A., Girard, L., McFarlane, P. A., MOIST, L. M., Nessim, S. J., Soroka, S. D., Stafford, S. G., Steele, A., Tangri, N., et al. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221150556 · Cited by 18

Protective effect of heat-processed Gynostemma pentaphyllum on high fat diet-induced glucose metabolic disorders mice

Xie, J., Xie, P., Guo, M. L., Li, F., Xiao, M., Qi, Y.-S., Pei, W., Luo, H.-T., Gu, Y., & Piao, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1215150 · Cited by 16

HMGN1 down-regulation in the diabetic kidney attenuates tubular cells injury and protects against renal inflammation via suppressing MCP-1 and KIM-1 expression through TLR4

Yu, J., Da, J., Yu, F., Yuan, J., & Zha, Y. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02292-0 · Cited by 20

The neuromedin U system: Pharmacological implications for the treatment of obesity and binge eating behavior

Botticelli, L., Bonaventura, E. M. D., Bello, F. D., Giorgioni, G., Piergentili, A., Quaglia, W., Bonifazi, A., Cifani, C., & Bonaventura, M. V. M. D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106875 · Cited by 16

Stratification of obesity phenotypes to optimize future therapy (SOPHIA)

Tahrani, A. A., Panova‐Noeva, M., Schloot, N. C., Hennige, A. M., Söderberg, J. A. E., Nadglowski, J. F., Tarasenko, L. C., Ahmad, N. N., Sleypen, B. S., Bravo, R., et al. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2264783 · Cited by 15

Diabetes mellitus: interdisciplinary medical, surgical and psychological therapeutic approach

Socea, B., Silaghi, A. M., Rebegea, L. F., Bălan, D. G., Bălălău, C., Ţenea-Cojan, T. Ş., Mihai, D. A., & Păunică, I. (2023) · Journal of Mind and Medical Sciences · doi:10.22543/2392-7674.1445 · Cited by 16

Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus

Suzuki, Y., Kaneko, H., Okada, A., Ohno, R., Yokota, I., Fujiu, K., Jo, T., Takeda, N., Morita, H., Node, K., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02246-6 · Cited by 15

Social determinants of diabesity and its association with multimorbidity among older adults in India: a population-based cross-sectional study

Sinha, A., Puri, P., & Pati, S. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061154 · Cited by 14

AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus

Berra, C., Manfrini, R., Mirani, M., Bucciarelli, L., Zakaria, A., Piccini, S., Ghelardi, R., Lunati, M. E., Rodovalho, S., Bifari, F., et al. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02115-x · Cited by 13

Neuroprotective and Cardiometabolic Role of Vitamin E: Alleviating Neuroinflammation and Metabolic Disturbance Induced by AlCl3 in Rat Models

Jabeen, K., Rehman, K., Akash, M. S. H., Nadeem, A., & Mir, T. M. (2023) · Biomedicines · doi:10.3390/biomedicines11092453 · Cited by 14

The effect of subcutaneous dulaglutide on weight loss in patients with Type 2 diabetes mellitus: Systematic review and meta‐analysis of randomized controlled trials

Li, Y., Gong, X., Găman, M., Hernández‐Wolters, B., Velu, P., & Li, Y. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14125 · Cited by 16

Senna petersiana (Bolle) leaf extract modulates glycemic homeostasis and improves dysregulated enzyme activities in fructose-fed streptozotocin-induced diabetic rats

Olofinsan, K. A., Salau, V. F., Erukainure, O. L., & Islam, M. S. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115998 · Cited by 14

Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists

Kobayashi, K., Toyoda, M., Hatori, N., Sakai, H., Furuki, T., Chin, K., Kimura, M., Saito, N., Kanaoka, T., Aoyama, T., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109231 · Cited by 15

Can Polyherbal Medicine be used for the Treatment of Diabetes? - A Review of Historical Classics, Research Evidence and Current Prevention Programs

Brahma, S., Goyal, A. K., Prakash, D., Kumari, M. R., Sadasivam, J., Usha, T., & Middha, S. K. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230314093721 · Cited by 13

Tirzepatide: Clinical review of the twincretin injectable

Krauss, Z., Hintz, A., & Fisk, R. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad080 · Cited by 12

Psychotropic effects of GLP-1R agonists

Bucciarelli, L. G., Cimino, V., Dell’Osso, B. M., & Fiorina, P. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108036 · Cited by 13

Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study

Abutaima, R., Barakat, M. M., Sawan, H. M., Omari, S. M. A., & Mhaidat, N. M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314407 · Cited by 12

Effect of empagliflozin on weight in patients with prediabetes and diabetes

Sanjari, M., Hadavizadeh, M., Sadeghi, N., & Naghibzadeh‐Tahami, A. (2025) · Scientific Reports · doi:10.1038/s41598-024-83820-7 · Cited by 14

Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis

Ciccarelli, G., Giuseppe, G. D., Cinti, F., Moffa, S., Mezza, T., & Giaccari, A. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3668 · Cited by 11

Dapagliflozin attenuates fat accumulation and insulin resistance in obese mice with polycystic ovary syndrome

Lin, B., Guo, X., Lü, W., Niu, R. L., Zeng, X., Chen, Z., Wu, C., & Liu, C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176742 · Cited by 10

Morus alba: natural and valuable effects in weight loss management

Ntalouka, F., & Tsirivakou, A. (2024) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2024.1395688 · Cited by 10

Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis

Chen, B., Tao, L., Tian, M., & Ji, Z. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.01.056 · Cited by 10

Dapagliflozin mitigates cognitive deficits in a rat model of chronic restrained stress by addressing insulin resistance and mitochondrial dysfunction

Gamal, N., Bakly, W. M. S. E., Saad, S. S. T., El-Waseef, D. A. E.-D. A., El‐Shal, A. S., Morsy, W. E., & Magdy, Y. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04136-5 · Cited by 10

Does gestational diabetes mellitus increase the risk of cardiovascular disease? A Mendelian randomization study

Liang, W., & Sun, F. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02233-x · Cited by 12

Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition

Agcakaya, E., Mutlu, H. H., Erbakan, A. N., & Sargın, M. (2023) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2023.03.308 · Cited by 9

Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations

Ogunsanmi, D., Harrison, A., Pakker, A. R., Kovesdy, C. P., Bailey, J. E., & Surbhi, S. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.6.699 · Cited by 9

Responsible Use of Oral Corticosteroids in People with Comorbid Diabetes: An Expert Consensus

Saboo, B., Joshi, S., Gupta, A. S., Maheshwari, A., Saboo, B., Makkar, B. M., Bantwal, G., Kesavadev, J., Murthy, L. S., TIWASKAR, M. H., et al. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0573 · Cited by 9

Natural sulfated polysaccharides as biomacromolecule in management of metabolic disorders: A comprehensive review

Kalita, P., Pathak, M. P., Barbhuiya, P. A., & Nongkhlaw, F. T. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144856 · Cited by 8

A New Strategy for Obesity Treatment: Revealing the Frontiers of Anti-obesity Medications

Huang, P.-T., Wang, Q., Chen, R., Wang, Y., Wang, Y.-Y., Liu, J., Xiao, X., & Liao, Z. (2024) · Current Molecular Medicine · doi:10.2174/0115665240270426231123155924 · Cited by 8

TNFSF14-Derived Molecules as a Novel Treatment for Obesity and Type 2 Diabetes

Agostino, M., Rooney, J. K., Herat, L. Y., Matthews, J. R., Simonds, A., Northfield, S. E., Hopper, D., Schlaich, M. P., & Matthews, V. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910647 · Cited by 8

Depolymerization of oyster glycosaminoglycans for the enhancement of α-glucosidase inhibition and its application in hypoglycemic studies

Yan, G., Wang, Y., Yu, L., Bo, J., Fang, H., Chen, W., Zhang, Y., Chen, H., & Hong, Z. (2025) · Food Research International · doi:10.1016/j.foodres.2025.116008 · Cited by 7

Individualized diabetes care: Lessons from the real-world experience

Khor, X. Y., Pappachan, J. M., & Jeeyavudeen, M. S. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i13.2890 · Cited by 12

Effectiveness of Dapagliflozin as Add-On to Metformin with or without Other Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Database Study

Sethi, B. K., Sahay, R. K., TIWASKAR, M. H., Negalur, V. B., Dhediya, R., Gaurav, K., Rathod, R., Kotak, B., Dhanaki, G. D., & Shah, S. P. (2023) · Drugs - Real World Outcomes · doi:10.1007/s40801-023-00398-8 · Cited by 7

Novel antioxidative and hypoglycemic collagen peptides from Apostichopus japonicus: in silico preparation, functional mechanism, and structure–activity relationship study

Zhang, B., Ren, L., Lu, Y., Wang, Z., Zhang, G., Liu, Z., Wang, Y., Zhu, F., Li, X., Jiang, Y., et al. (2025) · Food Chemistry · doi:10.1016/j.foodchem.2025.145695 · Cited by 6

Understanding the Increasing Prevalence of Obesity in Patients With Type 1 Diabetes: Strategies for Improving Clinical Care

Ruddiman, K. R., Bartfield, J. K., & Hirsch, I. B. (2025) · Obesity · doi:10.1002/oby.70033 · Cited by 8

Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management

Rabbani, S. A., El‐Tanani, M., Matalka, I. I., Rangraze, I. R., Aljabali, A. A. A., Khan, M. A., & Tambuwala, M. M. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2395540 · Cited by 8

Differential Efficacy of Weight Loss Interventions in Patients with Versus Without Diabetes

Losada-Díaz, F., Lizarazo-Bocanegra, S., Perdomo-Lugo, J. J., Gutiérrez-Romero, S. A., Correa-Osio, I., & Mendivil, C. O. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01646-y · Cited by 7

Beyond weight: Exploring the nexus between obesity and osteoarthritis

Ningtyas, M. C., Ansharullah, B. A., Sutanto, H., & Prajitno, J. H. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102526 · Cited by 6

Transplantation of insulin‐producing cells derived from human MSCs to treat diabetes in a non‐human primate model

Zhu, Z., Bingzheng, F., Yuwei, Y., Yingying, Z., Xu, Z., Chunhua, H., Jing, L., Tang, H., Wanli, L., Zhang, T., et al. (2023) · Artificial Organs · doi:10.1111/aor.14538 · Cited by 6

SGLT2-Inhibitors are Effective and Safe in the Elderly: The SOLD StudyPreprint

Lunati, M. E., Cimino, V., Gandolfi, A., Trevisan, M., Montefusco, L. B., Pastore, I., Pace, C., Betella, N., Favacchio, G., Bulgheroni, M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4135997 · Cited by 6

Protein–Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection

Petsas, E., Kiouri, D. P., Georgiou, N., Siasos, G., Mavromoustakos, T., & Chasapis, C. T. (2025) · Molecules · doi:10.3390/molecules30214240 · Cited by 6

Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP/GLP-1 receptor agonists- preliminary study

Korus, S., Cembrowska-Lech, D., Kłoda, K., & Stachowska, E. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07702-4 · Cited by 5

Therapeutic Repurposing of Antidiabetic Drugs in Diabetes-associated Comorbidities

Pathak, K., Pathak, M. P., Saikia, R., Gogoi, U., Das, R. J., Patowary, P., Kaishap, P. P., Bordoloi, S., Das, J., Sarma, H., et al. (2023) · Current Drug Therapy · doi:10.2174/1574885518666230516150404 · Cited by 6

Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy

Sun, X., Yang, D., Li, Y., Shi, J., Zhang, X., & Yi, T. (2024) · Peptides · doi:10.1016/j.peptides.2024.171203 · Cited by 5

RGB Trichromatic Whiteness Assessment of Bio Analytical Chromatographic Tool Using Fluorescence for Quantitation of Semaglutide: Application to Pharmaceutical Preparations and Spiked Plasma

Moneim, M. M. A., Kamal, M. F., & Hamdy, M. M. A. (2024) · Journal of Fluorescence · doi:10.1007/s10895-024-03954-9 · Cited by 5

csi-miR166e, A Microribonucleic Acid of Considerable Abundance in Plant Food, Ameliorates High-Fat Diet/Streptozotocin-Induced Type 2 Diabetes in Mice via Oral Administration

Li, Y., Xu, Q., Wang, J., Xin, Y., Zhang, Y., Qin, X., Xu, K., Yang, X., & Wang, X. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c07282 · Cited by 5

Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus

Talebi, S. S., Rezaie, S., Hajmiri, M. S., Zamanirafe, M., Ranjbar, A., Moridi, H., Mirjalili, M., & Mehrpooya, M. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03219-z · Cited by 10

Dietitian‐supported dietary intervention leads to favorable dietary changes in patients with type 2 diabetes: A randomized controlled trial

Kawabata, N., Okada, K., Ando, A., Kurashina, T., Takahashi, M., Wakabayashi, T., Nagata, D., Arakawa, Y., Atsuko, H., Kogure, A., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13890 · Cited by 5

The role of the incretin GIP in inflammation

Rossi, G., Bucciarelli, L. G., Cimino, V., & Fiorina, P. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02719-w · Cited by 4

2025 Brazilian evidence-based guideline on the management of obesity and prevention of cardiovascular disease and obesity-associated complications: a position statement by five medical societies

Valério, C. M., Saraiva, J. F. K., Valente, F., van de Sande‐Lee, S., Rocha, V. Z., Rached, F. H., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01954-8 · Cited by 8

Dietary Fiber and Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Converging Mechanisms, Interactions, and Strategies for Durable Weight Control

Wang, Y., Liu, J., Verbeke, K., Gasaly, N., Akkerman, R., & de Vos, P. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100647 · Cited by 6

Synthesis, characterization, and in vitro and in silico α-glucosidase inhibitory evolution of novel N ′-(2-cyclopentyl-2-phenylacetyl)cinnamohydrazide derivatives

Mudireddy, R. R., Gundla, R., Shaik, B. B., Bodapati, A., Mahesh, P., Naidu, S. S., Tirumalasetti, D., & Katari, N. K. (2025) · RSC Advances · doi:10.1039/d5ra01971k · Cited by 4

Multiple beneficial effects of 1-year nutritional–behavioral intervention on anthropometric and metabolic parameters in overweight and obese boys

Tosi, M., Matelloni, I. A., Mancini, M., Andreassi, A., Scopari, A., Rossi, A., Verduci, E., Berra, C., Manfrini, R., Banderali, G., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02088-2 · Cited by 5

Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes

Hurren, K. M., & Dunham, M. W. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494727 · Cited by 20

Recent advances in the treatment of type 2 diabetes mellitus with obesity

Yargin, S. V. (2021) · DOAJ (DOAJ: Directory of Open Access Journals)

The Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight

Pi-Sunyer, X. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.07.1785 · Cited by 49

The role of anti-obesity drugs in the management of obese diabetics

Micić, D., Polovina, S. P., & Micić, D. (2018) · Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma · doi:10.5937/medgla1870015m

The impact of pharmacotherapy on weight management in type 2 diabetes

Hauner, H. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800956 · Cited by 33